within Pharmacolibrary.Drugs.ATC.C;

model C09XA02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.025,
    Cl             = 0.825,
    adminDuration  = 600,
    adminMass      = 0.3,
    adminCount     = 1,
    Vd             = 0.135,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005183333333333333,
    Tlag           = 22.8
  );

  annotation(Documentation(
    info ="<html><body><p>Aliskiren is a direct renin inhibitor used primarily for the treatment of hypertension. It reduces plasma renin activity and lowers blood pressure. Aliskiren is approved for clinical use in several countries, though its usage may be limited due to safety concerns in some specific patient populations.</p><h4>Pharmacokinetics</h4><p>Reported values in healthy adult subjects after single oral administration.</p><h4>References</h4><ol><li>Sujata Vaidyanathan, Venkateswar Jarugula, Hans Armin Dieterich, Dan Howard, William P Dole,Clinical pharmacokinetics and pharmacodynamics of aliskiren.,Clinical pharmacokinetics,2008<a href='https://pubmed.ncbi.nlm.nih.gov/18611061/'>https://pubmed.ncbi.nlm.nih.gov/18611061/</a></li><li>Kimberly K Daugherty,Aliskiren.,American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,2008<a href='https://pubmed.ncbi.nlm.nih.gov/18593678/'>https://pubmed.ncbi.nlm.nih.gov/18593678/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C09XA02;
